Medicina (Feb 2022)

Ferroptosis Involvement in Glioblastoma Treatment

  • Andrei-Otto Mitre,
  • Alexandru Ioan Florian,
  • Andrei Buruiana,
  • Armand Boer,
  • Ioana Moldovan,
  • Olga Soritau,
  • Stefan Ioan Florian,
  • Sergiu Susman

DOI
https://doi.org/10.3390/medicina58020319
Journal volume & issue
Vol. 58, no. 2
p. 319

Abstract

Read online

Glioblastoma multiforme (GBM) is one of the deadliest brain tumors. Current standard therapy includes tumor resection surgery followed by radiotherapy and chemotherapy. Due to the tumors invasive nature, recurrences are almost a certainty, giving the patients after diagnosis only a 12–15 months average survival time. Therefore, there is a dire need of finding new therapies that could potentially improve patient outcomes. Ferroptosis is a newly described form of cell death with several implications in cancer, among which GBM. Agents that target different molecules involved in ferroptosis and that stimulate this process have been described as potentially adjuvant anti-cancer treatment options. In GBM, ferroptosis stimulation inhibits tumor growth, improves patient survival, and increases the efficacy of radiation and chemotherapy. This review provides an overview of the current knowledge regarding ferroptosis modulation in GBM.

Keywords